AstraZeneca's Multi-Billion Dollar Cancer Drug Tagrisso Improves Overall Survival In Patients With Advanced Lung Cancer

benzinga.com/news/health-care/25/07/46534118/astrazenecas-multi-billion-dollar-cancer-drug-tagrisso-improves-overall-survival-in-patients-wit

On Monday, AstraZeneca Plc (NASDAQ:AZN) released high-level results from the final overall survival (OS) analysis of the FLAURA2 Phase 3 trial of Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy.
The study demonstrated a statistically significant and…

This story appeared on benzinga.com, 2025-07-21 21:57:48.
The Entire Business World on a Single Page. Free to Use →